Keywords: Biogen Idec, Knopp, ALS, Lou Gehrig's disease, Licensing

Biogen Idec licenses Knopp’s late-stage ALS drug candidate for up to $345 million

Article | 19 August 2010

Print This

US biotech firm Biogen Idec has entered into an exclusive, worldwide license agreement with Knopp Neurosciences under which it will ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in